ExxonMobil Releases 2Q 2024 Impact Factors

By Bobby Samwell • Monday, July 08 07:52 • Permanent Link

ExxonMobil has released a summary of factors that are expected to impact its 2Q 2024 results compared to the 1Q 2024 results. Here are the key figures:

1Q 2024 Earnings (Loss), U.S. GAAP: Upstream: $5.7 billion Energy products: $1.4 billion Chemical products: $0.8 billion Specialty products: $0.8 billion Corp & Fin: ($0.4 billion) Total: $8.2 billion

1Q 2024 Earnings (Loss) Excluding Identified Items (Non-GAAP): Upstream: $5.7 billion Energy products: $1.4 billion Chemical products: $0.8 billion Specialty products: $0.8 billion Corp & Fin: ($0.4 billion) Total: $8.2 billion

Estimated Effects of Market Factors Impacting 2Q 2024 Results: Change in liquids prices: $0.3 * $0.7 billion Change in gas prices: ($0.7) * ($0.3) billion Change in industry margins: ($1.5) * ($1.1) billion Specialty products: $0.0 * $0.2 billion * Corp & Fin: ($0.1) * $0.1 billion

Estimated Effects of Planned and Seasonal Factors, and Other Items Impacting 2Q 2024 Results: * Change in scheduled maintenance: Upstream: ($0.2) * $0.0 billion; Energy products: 0.1 * 0.3 billion; Chemical products: ($0.1) * 0.1 billion; Specialty products: ($0.1) * 0.1 billion

2Q 2024 Additional Impacts from the Acquisition of Pioneer Natural Resources: Production (koebd): 1500 * 550 Earnings (Loss), U.S. GAAP: $0.2 * 0.4 billion Pre-tax dd&a: 0.9 * 1.1 billion Capex: 0.7 * 0.9 billion * EM Avg. shares outstanding (million): ~4,250

These figures provide insights into the estimated impacts on ExxonMobil's overall 2Q 2024 results, including the effects of market factors, planned and seasonal factors, and the acquisition of Pioneer Natural Resources. As a result of these announcements, the company's shares have moved -1.2% on the market, and are now trading at a price of $113.37. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.